PCR And Realtime PCR Testing Market Report 2026

PCR And Realtime PCR Testing Market Overview

• PCR And Realtime PCR Testing market size has reached to $11.12 billion in 2025 • Expected to grow to $16.38 billion in 2030 at a compound annual growth rate (CAGR) of 8% • Growth Driver: Rising Approvals For Personalized Medicines Is Anticipated To Fuel Pcr And Real-Time Pcr Testing Market • Market Trend: Roche Launches Variant-Specific Real-Time PCR Assay To Enhance SARS-CoV-2 Surveillance • Asia-Pacific was the largest region in 2025 and Western Europe is the fastest growing region.

What Is Covered Under PCR And Realtime PCR Testing Market?

Polymerase chain reaction (PCR) and Real-time Polymerase chain reaction (PCR) tests are used to detect and measure the DNA (or RNA) in a sample. These tests are conducted in automated thermal cyclers less sensitive to cross-contamination. It finds applications in cloning, genotyping, mutation testing, paternity testing, sequencing, and microarrays. The main products of polymerase chain reaction (PCR) and real-time polymerase chain reaction (PCR) testing are consumables, reagents, instruments, software, and services. The technologies involved in PCR and real-time PCR testing are quantitative PCR and digital PCR which provide various applications such as clinical diagnostics, life science research, industrial applications, and others. The market covered in this report is segmented by end-use into academic and research institutes, pharmaceutical and biotechnology, clinical diagnostics labs and hospitals, and others.

What Is The PCR And Realtime PCR Testing Market Growth Forecast?

The pcr and realtime pcr testing market size is expected to see strong growth in the next few years. It will grow to $16.38 billion in 2030 at a compound annual growth rate (CAGR) of 8.0%. The growth in the forecast period can be attributed to increasing demand for personalized medicine, rising adoption of digital pcr technologies, expansion of decentralized diagnostic testing, growing investments in life science research, increasing use of pcr in oncology and genetic testing. Major trends in the forecast period include increasing adoption of high-throughput pcr platforms, rising demand for multiplex real-time pcr assays, growing integration of automated sample preparation systems, expansion of digital pcr applications, enhanced focus on contamination-free testing.

Global PCR And Realtime PCR Testing Market Segmentation

1) By Product: Consumables And Reagents, Instruments, Software And Services 2) By Technology: Quantitative PCR, Digital PCR 3) By Application: Clinical Diagnostics, Life Science Research, Industrial Applications, Other Applications 4) By End-Use: Academic And Research Institutes, Pharmaceutical And Biotechnology, Clinical Diagnostics Labs And Hospitals, Other End Users Subsegments: 1) By Consumables And Reagents: PCR Reagents, PCR Kits, PCR Primers And Probes, DNA And RNA Extraction Kits 2) By Instruments: PCR Machines/Amplifiers, Real-Time PCR Systems, Thermal Cyclers, Automated PCR Systems 3) By Software And Services: Data Analysis Software, PCR Software, Maintenance And Support Services, Training Services

What Is The Driver Of The PCR And Realtime PCR Testing Market?

The rising approvals for personalized medicines are expected to propel the PCR And real-time PCR testing market going forward. Personalized medicines refer to therapeutic products or treatments tailored to the individual patient. They are designed based on a patient's genetic, biomarker, phenotypic, or psychosocial characteristics that can predict an individual's response to a treatment. PCR and Real-Time PCR in personalized medicine enables the precise identification of genetic variations, which helps tailor treatments to individual patient needs and optimize therapeutic outcomes. For instance, in February 2024, according to the Personalised Medicine Coalition, a US-based hospital and health care organization, in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. Therefore, the rising approvals for personalized medicines drive the PCR And real-time PCR testing market.

Key Players In The Global PCR And Realtime PCR Testing Market

Major companies operating in the pcr and realtime pcr testing market are Abbott Laboratories, Agilent Technologies Inc., bioMérieux SA, Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd., QIAGEN N.V., GenMark Diagnostics Inc., Thermo Fisher Scientific Inc., General Electric Company, Danaher Corporation, Becton Dickinson and Company, Luminex Corporation, Meridian Bioscience Inc., Fluidigm Corporation, RainDance Technologies Inc., BioFire Diagnostics LLC, Cepheid Inc., Illumina Inc., Oxford Nanopore Technologies Ltd., Pacific Biosciences of California Inc., Promega Corporation, Takara Bio Inc., Twist Bioscience Corporation, Zymo Research Corporation, BioChain Institute Inc., BioLegend Inc., Bioo Scientific Corporation, Creative Diagnostics, Eurofins Scientific SE, Myriad Genetics Inc.

Global PCR And Realtime PCR Testing Market Trends and Insights

Major companies operating in the PCR and real time PCR testing market are developing highly specific detection kits, such as variant targeted RT PCR assays, to better track viral evolution and support epidemiological surveillance. Variant-targeted RT PCR assays are molecular diagnostic tests designed to detect specific genetic mutations or variations within a virus, enabling precise identification of particular viral strains or sub-variants. For instance, in January 2023, Roche, a Switzerland based diagnostics company, introduced the VirSNiP SARS CoV 2 Spike F486P assay, a real time PCR test that specifically detects the F486P mutation in the XBB.1.5 Omicron sub-variant. This kit runs on standard real-time PCR platforms such as LightCycler 480 II and cobas z 480, and provides researchers with precise lineage differentiation to aid in variant monitoring.

What Are Latest Mergers And Acquisitions In The PCR And Realtime PCR Testing Market?

In February 2025, Bio Rad Laboratories, a US based provider of life science research and clinical diagnostics products, acquired Stilla Technologies for an undisclosed amount. With this acquisition, Bio Rad aims to integrate Stilla’s next generation digital PCR systems into its portfolio to accelerate innovation in molecular diagnostics across applications such as infectious disease testing, oncology, and cell therapy. Stilla Technologies is a US based developer of all in one digital PCR platforms, consumables, and assays for high-multiplex and high-throughput molecular testing.

Regional Outlook

Asia-Pacific was the largest region in the PCR and real-time PCR testing market in 2025. Western Europe was the second-largest region in the PCR and real-time PCR testing market. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the PCR And Realtime PCR Testing Market?

The PCR and Real-time PCR testing market consists of sales of genetic sequencing equipment such as automated thermo cyclers with technologies such as quantitative PCR and digital PCR for cloning, genotyping, mutation testing, paternity testing, sequencing, and microarrays. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.